Skip to main content

Advertisement

SpringerLink
Log in

Colitis Associated with Biological Agents

  • UNM Clinical Case Conferences
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–2697.

    Article  CAS  PubMed  Google Scholar 

  2. Freeman HJ. Colitis associated with biological agents. World J Gastroenterol. 2012;18:1871–1874.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Fouache D, Goëb V, Massy-Guillemant N, Avenet G, et al. Paradoxical adverse events of anti-tumor necrosis factor therapy for spondylo-arthropathies: a retrospective study. Rheumatology. 2009;48:761–764.

    Article  CAS  PubMed  Google Scholar 

  4. Mitchell KA, Kluger H, Sznol M, Hartman DJ. Ipilimumab-induced perforating colitis. J Clin Gastroenterol. 2013;47:781–785.

    Article  PubMed  Google Scholar 

  5. Blansfield JA, Beck KE, Tran K, Yang JC, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28:593–598.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 4.0. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2010. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.

  7. Beck KE, Blansfield JA, Tran KQ, Feldman AL, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283–2289.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm. 2009;24:321–325.

    Article  CAS  PubMed  Google Scholar 

  9. Pagès C, Gornet JM, Monsel G, Allez M, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23:227–230.

    Article  PubMed  Google Scholar 

  10. Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54:2538–2540.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, 1 University of New Mexico, MSC10-5550, Albuquerque, NM, 87131, USA

    K. Khirfan & M. Kistin

Authors
  1. K. Khirfan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Kistin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Khirfan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khirfan, K., Kistin, M. Colitis Associated with Biological Agents. Dig Dis Sci 59, 1112–1114 (2014). https://doi.org/10.1007/s10620-014-3147-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-014-3147-x

Keywords

Search

Navigation